Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 26;14:1087986. doi: 10.3389/fimmu.2023.1087986

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Frede, Lorenzetti, Hüppe, Janowska, Troilo, Schleyer, Venhoff, Voll, Thiel, Venhoff and Rizzi

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

B cell phenotyping of RA patients under JAK inhibitor treatment. (A) PBMCs from 25 RA patients under JAK inhibitor treatment (16 baricitinib, 8 tofacitinib, 1 upadacitinib) as well as 30 healthy donors were stained with fluorochrome-labelled antibodies to assess expression of surface markers by spectral flow cytometry (Cytek Aurora). Gating strategy depicted in Supplementary Figure 1A. Statistical analysis by t-test, **p < 0.005, 0.0005, ****p < 0.0001; ns, not significant. (B) B-cell subpopulations of 10 RA patients before and under JAK inhibitor therapy. Data depicted as percent of baseline. PB, plasmablasts; MZ-like, marginal zone-like B cells; SM, switched memory B cells; Bari, baricitinib; Tofa, tofacitinib.